Company Profile
FutureChem develops, produces, and sells chemicals, pharmaceuticals, and medical devices in South Korea and globally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products in pipeline include [18F]FC303, [177Lu]FC705, and 225Ac for the treatment of prostate cancer.
Its portfolio also includes F-FMT for brain tumor diagnosis, FC-505 for the treatment of arteriosclerosis and myocardial infarction, FC-211 for Alzheimer's disease, FC-2 for the treatment of hypoxia, FC-3 for solid cancer, FC801 for bladder cancer, and FC901 for the treatment of pulmonary fibrosis
Automatic synthesis equipment, such as sCUBE-RXN (synthetic), sCUBE-P&F (tablet-formulation), and sCUBE-M (radioactive, metal). Additionally, it offers molecular imaging device airway sleeve and disposable cartridges, as well as engages in medical device wholesale and healthcare business. Founded in 1999, FutureChem is headquartered in Seoul, South Korea.